<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04956952</url>
  </required_header>
  <id_info>
    <org_study_id>P00037795</org_study_id>
    <nct_id>NCT04956952</nct_id>
  </id_info>
  <brief_title>Enhanced External Counterpulsation in Patients With Fontan Circulation</brief_title>
  <official_title>Enhanced External Counterpulsation in Patients With Fontan Circulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the proposed study is to determine the safety of enhanced external&#xD;
      counterpulsation (EECP), a system for compressing the blood vessels in the legs in synchrony&#xD;
      with an individual's cardiac rhythm, in clinically well, adult Fontan patients, to document&#xD;
      the acute hemodynamic and myocardial effects of EECP on the Fontan circulation, and to&#xD;
      demonstrate acute changes in endothelial function after one hour of the procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators plan to study the effects of enhanced external counterpulsation (EECP), on&#xD;
      patients who have had Fontan surgery for treatment of complex congenital heart disease.&#xD;
      Eligible patient volunteers will undergo a series of biophysical measurements at rest&#xD;
      including echocardiographic assessment of ventricular function, pulmonary blood flow/cardiac&#xD;
      output measurement using an inert gas rebreathing method (Innocor), and measurements of&#xD;
      biomarkers of endothelial function (ET-1, NOx). Patients will then undergo 1 hour of&#xD;
      treatment with EECP, during which additional echocardiographic assessment of ventricular&#xD;
      function and pulmonary blood flow/cardiac output measurements will be performed at multiple&#xD;
      levels of leg compression. Subjects will be assessed periodically for adverse effects and&#xD;
      discomfort during the EECP treatment. At the completion of treatment, patients will be&#xD;
      allowed 30 minutes to rest before undergoing one more echocardiographic assessment of&#xD;
      ventricular function, pulmonary blood flow/cardiac output measurement, and measurements of&#xD;
      biomarkers of endothelial function (ET-1, NOx). Measurements made during and after treatment&#xD;
      will be compared to baseline measurements.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cardiac output</measure>
    <time_frame>Immediately prior to starting EECP treatment, during each 20-minute phase of EECP treatment, and 30 minutes after EECP treatment</time_frame>
    <description>Measurement of cardiac output (pulmonary blood flow) in L/min using inert gas rebreathing method (Innocor CO device)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total number and type of adverse events during EECP treatment</measure>
    <time_frame>During EECP treatment (duration 60 minutes)</time_frame>
    <description>Adverse events will be collected by an investigator and documented using CTCAE criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total number and type of adverse events immediately following EECP treatment</measure>
    <time_frame>From completion of EECP treatment until patient discharge (30 to 60 minutes)</time_frame>
    <description>Adverse events will be collected by an investigator and documented using CTCAE criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in ventricular strain analysis</measure>
    <time_frame>Immediately prior to starting EECP treatment, during each 20-minute phase of EECP treatment, and 30 minutes after EECP treatment</time_frame>
    <description>Global mid-ventricle circumferential strain (%) and global longitudinal strain (%) calculated from speckle-tracking echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in qualitative ventricular systolic function</measure>
    <time_frame>Immediately prior to starting EECP treatment, during each 20-minute phase of EECP treatment, and 30 minutes after EECP treatment</time_frame>
    <description>Qualitative assessment of systolic function of dominant ventricle on 2-dimensional echocardiography, categorized as normal, low normal to mildly depressed, mildly depressed, mildly to moderately depressed, moderately depressed, moderately to severely depressed, severely depressed, or unable to determine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma endothelin (ET-1)</measure>
    <time_frame>pre and 30 minutes post EECP treatment</time_frame>
    <description>This will measure endothelial function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total nitrate/nitrite (NOx) levels</measure>
    <time_frame>pre and 30 minutes post EECP treatment</time_frame>
    <description>This will measure endothelial function</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Single-ventricle</condition>
  <condition>Congenital Heart Disease</condition>
  <arm_group>
    <arm_group_label>Enhanced External Counterpulsation (EECP)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>1 hour of treatment with EECP</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EECP</intervention_name>
    <description>1 hour of treatment with EECP</description>
    <arm_group_label>Enhanced External Counterpulsation (EECP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals with Fontan physiology being seen in the Boston Children's Hospital&#xD;
             cardiology clinic for outpatient care.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current pregnancy&#xD;
&#xD;
          -  Decompensated heart failure/pulmonary edema&#xD;
&#xD;
          -  Severe aortic insufficiency&#xD;
&#xD;
          -  Active tachyarrhythmias&#xD;
&#xD;
          -  Frequent atrial or ventricular ectopy&#xD;
&#xD;
          -  Symptomatic peripheral vascular disease&#xD;
&#xD;
          -  Thrombophlebitis or history of deep vein thrombosis or stasis ulcer&#xD;
&#xD;
          -  Aortic aneurysm&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic blood pressure &gt;180 mmHg or diastolic blood&#xD;
             pressure&gt;110 mmHg)&#xD;
&#xD;
          -  Systolic blood pressure &lt;90 mmHg&#xD;
&#xD;
          -  Active femoral site bleeding or hematoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fred Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Attending Cardiologist</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fred Wu, MD</last_name>
    <phone>617-355-7893</phone>
    <email>fred.wu@cardio.chboston.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erica Denhoff, MPH</last_name>
    <email>erica.denhoff@childrens.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fred Wu, MD</last_name>
      <phone>617-355-7893</phone>
      <email>fred.wu@cardio.chboston.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 1, 2021</study_first_submitted>
  <study_first_submitted_qc>July 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children's Hospital</investigator_affiliation>
    <investigator_full_name>Fred Wu, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Fontan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Univentricular Heart</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

